ArticleScientific reports2025
Integrative pharmacogenomics analysis predicts the platelet response in clopidogrel treated coronary artery disease (CAD) patients of South India.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent research progress on the mechanisms of clopidogrel resistance.European journal of clinical pharmacology · 2026Review
- Several antiplatelet gene SNPs, their haplotypes andFrontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Clopidogrel resistance/high on-treatment platelet reactivity (HTPR) has been associated with interindividual variability in the clopidogrel treatment response in different ethnicities leading to adverse coronary events. The current study evaluated the effect of genetics and clinical factors on platelet inhibition in clopidogrel-treated South Indian CAD patients. We genotyped 15 genetic polymorphisms in the genes associated with the pharmacokinetics and pharmacodynamics of clopidogrel. We observed a high prevalence of the poor metabolizer CYP2C19*2 (34%) variant and CYP2C19-based high-risk metabolizer phenotype such intermediate and poor metabolizer (IM + PM) with 68.5% in CAD patients. The platelet function test revealed that 31% of the CAD cases were HTPR phenotypes (VASP PRI > 50%). The CYP2C19*2 [OR 2.37 (95% CI 1.16-4.84), p = 0.02], high risk CYP2C19 metabolizer phenotypes [OR 1.72 (95% CI 1.08-2.77), p = 0.02] showed increased risk of HTPR. However, PON1 (rs662) favoured better response to clopidogrel [OR 0.50 (95% CI 0.32-0.80), p = 0.004]. Similarily, the multivariate linear regression showed that the CYP2C19*2 (rs4244285) and P2RY12 (rs6809699) and clinical factors (BMI, type II diabetes, and biguanides usage) were associated with high platelet reactivity, while PON1 (rs662) contributed to better platelet inhibition by clopidogrel. The current study revealed predictive integrated pharmacogenomics tool to identify the genetic and clinical factors that determine the clopidogrel response for personalized therapeutic management of CAD patients of South Indian ethnicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.